Clinical Trial Audit and Monitoring Services - Overview
Clinical trial audit and monitoring ensure that trial data are accurate, complete, verifiable, and in agreement with ethical and scientific norms. Robust clinical trial monitoring is vital to protect scientific data integrity and yield valid Regulatory data. To ensure that clinical data adhere to the protocols and international guidelines, organizations must opt for clinical trial audit and monitoring services that can manage [Freyr1.1]the intricacies of bioavailability (BA) and bioequivalence (BE) studies.
Freyr’s clinical trial audit and monitoring services are delivered by a skilled team that demonstrates innovative problem-solving while monitoring everything from straightforward, 2-way, cross-over Bioequivalence (BE) and Bioavailability (BA) studies to large, complex, steady-state BE and BA study services. Freyr also provides independent clinical trial monitoring and auditing services for clinical and bio-analytical phases of the BE and BA studies through its highly qualified and experienced clinical study monitoring team. Our clinical experts guide clients in preparing and reviewing clinical SOPs to provide ongoing support for clinical trial audit and monitoring.
Freyr’s proactive, research-based approach helps clients access the best research sites by conducting a thorough feasibility audit and analyzing the CRO/study site, along with high-quality monitoring throughout the trial, to ensure compliance with applicable regulations and guidelines.
Clinical Trial Audit and Monitoring Services
- Clinical study monitoring services for phase I trials and bioequivalence studies
- Bio-analytical monitoring of phase I trial and bioequivalence studies
- Auditing of BE CRO/study site
- System audits of phase I-BE CRO/study site
- BA/ BE study monitoring services
- Preparation and review of clinical SOP

- In-depth clinical trial audit and monitoring knowledge perfectly integrated with IT capabilities
- Complete understanding of the complex drug development process, including new chemical entities (NCEs), generics, biologics, and biosimilars that facilitate clinical monitoring
- Vast experience in dealing with clinical trial audit imperatives across multiple therapeutic areas like oncology, cardiovascular, psychiatry, respiratory, renal, gastrointestinal, etc.
- Defined in-house processes for clinical trial monitoring to provide thorough scientific, medical, editorial, and quality control reviews before the sponsor review
